These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 618990)

  • 1. Interaction of human platelets with heparinized agarose gel.
    Lindon J; Rosenberg R; Merrill E; Salzman E
    J Lab Clin Med; 1978 Jan; 91(1):47-59. PubMed ID: 618990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endothelialization of crosslinked albumin-heparin gels.
    Bos GW; Scharenborg NM; Poot AA; Engbers GH; Beugeling T; van Aken WG; Feijen J
    Thromb Haemost; 1999 Dec; 82(6):1757-63. PubMed ID: 10613666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Catalytic activity and platelet reactivity of heparin covalently bonded to surfaces.
    Lindon JN; Salzman EW; Merrill EW; Dincer AK; Labarre D; Bauer KA; Rosenberg RR
    J Lab Clin Med; 1985 Feb; 105(2):219-26. PubMed ID: 3973461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discrimination between platelet-mediated and coagulation-mediated mechanisms in a model of complex thrombus formation in vivo.
    Cadroy Y; Horbett TA; Hanson SR
    J Lab Clin Med; 1989 Apr; 113(4):436-48. PubMed ID: 2522978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Interaction of heparinized polymer materials with plasma proteins and thrombocytes].
    Nemets EA; Sevastíanov VI
    Med Tekh; 1994; (2):18-22. PubMed ID: 8208096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of lysed platelets on neutralization of heparin in vitro with protamine as measured by the activated coagulation time (ACT).
    Bode AP; Castellani WJ; Hodges ED; Yelverton S
    Thromb Haemost; 1991 Aug; 66(2):213-7. PubMed ID: 1771614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Connective tissue activation XXXVIII: heparin/heparanase activity of human platelets resides in a high molecular weight protein, not in connective tissue activating peptide III.
    Castor CW; Kotlyar A; Edwards BE
    J Rheumatol; 2002 Nov; 29(11):2337-44. PubMed ID: 12415589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The contribution of anticoagulants to platelet dysfunction with extracorporeal circulation.
    Wallace HW; Brooks H; Stein TP; Zimmerman NJ
    J Thorac Cardiovasc Surg; 1976 Nov; 72(5):735-41. PubMed ID: 979314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction of antithrombin III with surface-immobilized albumin-heparin conjugates.
    van Delden CJ; Engbers GH; Feijen J
    J Biomed Mater Res; 1995 Nov; 29(11):1317-29. PubMed ID: 8582900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human platelet factor 4 and its C-terminal peptides: heparin binding and clearance from the circulation.
    Rucinski B; Niewiarowski S; Strzyzewski M; Holt JC; Mayo KH
    Thromb Haemost; 1990 Jun; 63(3):493-8. PubMed ID: 2402751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of heparin in tumor cell-induced platelet aggregation.
    Yamamoto K; Kitagawa H; Tanoue K; Tsuruo T; Yamamoto N; Yamazaki H
    Thromb Haemost; 1986 Aug; 56(1):90-4. PubMed ID: 3095948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interrelationship of protamine and platelet factor 4 in the neutralization of heparin.
    Shanberge JN; Quattrociocchi-Longe TM; Martens MH
    Thromb Res; 1987 Apr; 46(1):89-100. PubMed ID: 3590116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings.
    Greinacher A; Alban S; Omer-Adam MA; Weitschies W; Warkentin TE
    Thromb Res; 2008; 122(2):211-20. PubMed ID: 18262226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fate of thrombin and thrombin-antithrombin-III complex adsorbed to a heparinized biomaterial: analysis of the enzyme-inhibitor complexes displaced by plasma.
    Hatton MW; Rollason G; Sefton MV
    Thromb Haemost; 1983 Dec; 50(4):873-7. PubMed ID: 6198746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction of plasma proteins with heparinized gel particles studied by high-resolution two-dimensional gel electrophoresis.
    Ho CH; Hlady V; Nyquist G; Andrade JD; Caldwell KD
    J Biomed Mater Res; 1991 Apr; 25(4):423-41. PubMed ID: 1711049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exposure of fibrinogen-adherent platelets to plasma proteins: a new method for studying protein interactions with platelets.
    Broberg M; Nygren H
    J Biomed Mater Res A; 2003 Aug; 66(2):403-10. PubMed ID: 12889011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of low-molecular-weight heparin reversal by platelet factor 4.
    Fiore MM; Mackie IM
    Thromb Res; 2009 May; 124(1):149-55. PubMed ID: 19195682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Removal of heparin and protamine from plasma.
    Thompson AR; Counts RB
    J Lab Clin Med; 1976 Dec; 88(6):922-9. PubMed ID: 993645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased releasability of platelet products and reduced heparin-induced platelet factor 4 release from endothelial cells in bronchial asthma.
    Yasuba H; Chihara J; Kino T; Satake N; Oshima S
    J Lipid Mediat; 1991; 4(1):5-21. PubMed ID: 1832572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical study of platelet function and coagulation/fibrinolysis with Duraflo II heparin coated cardiopulmonary bypass equipment.
    Nakajima T; Osawa S; Ogawa M; Sasaki T; Izumoto H; Yagi Y; Kawazoe K
    ASAIO J; 1996; 42(4):301-5. PubMed ID: 8828788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.